Travere Therapeutics Q3 net product sales top $200M for first time

Travere Therapeutics reported strong third-quarter financial results, with net product sales surpassing $200 million for the first time, driven by demand for FILSPARI in IgA nephropathy and FSGS.

Detected & updated continuously · Source: Nebula